Welcome to our dedicated page for Adlai Nortye Ltd. SEC filings (Ticker: ANL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adlai Nortye Ltd. (NASDAQ: ANL) SEC filings page on Stock Titan provides access to the company’s public reports as a foreign private issuer, including Form 20-F annual reports and Form 6-K current reports. Adlai Nortye prepares its consolidated financial statements in accordance with IFRS as issued by the International Accounting Standards Board and presents its results in U.S. dollars, giving investors a standardized view of its clinical-stage biotechnology operations.
In its Form 6-K filings, the company reports unaudited financial information such as statements of operations, financial position, cash flows and changes in shareholders’ equity. These filings show that Adlai Nortye is a clinical-stage company with no reported revenue in the periods presented, and that its operating results are driven primarily by research and development and administrative expenses related to oncology drug development. They also disclose cash and restricted cash balances, interest-bearing bank borrowings, contract liabilities and accumulated deficits, helping readers assess liquidity and capital structure.
Beyond financial data, Adlai Nortye’s 6-Ks include narrative updates on its oncology pipeline, describing the status of programs such as Buparlisib (AN2025), AN4005, AN8025, AN9025, AN4035 and AN0025, as well as expectations for clinical milestones. Other filings detail governance matters, including adoption of the 2025 Share Incentive Plan, director resignations and appointments, committee composition and notices of shareholder meetings.
On Stock Titan, these filings are updated as they are posted to EDGAR, and AI-powered summaries can help explain key points in complex documents, from financial trends to pipeline disclosures and board changes. Users can review quarterly and semiannual financial updates, equity and incentive plan information, and other regulatory disclosures in one place when researching ANL stock and Adlai Nortye’s development trajectory.
Adlai Nortye Ltd. filed a Form F-3 shelf registration to offer up to US$600,000,000 of Class A ordinary shares and to register for resale up to 64,615,386 Class A ordinary shares (represented by 21,538,462 ADSs), from time to time after the effective date. The prospectus states the selling shareholders’ sales will provide no proceeds to the company, and that ADSs trade on Nasdaq under the symbol ANL. The prospectus describes the securities, dual-class share structure, risk factors including HFCAA-related delisting risk, and that specific offering terms will be provided in prospectus supplements.
Adlai Nortye Ltd. reported that the first patient has been dosed in a global Phase 1 clinical trial of AN9025, its oral pan-RAS(ON) inhibitor for advanced or metastatic solid tumors with RAS mutations. This first-in-human, multicenter, open-label study will assess safety, tolerability, pharmacokinetics and early anti-tumor activity.
The trial is being run as a multi-regional clinical trial in collaboration with ASK Pharm, with Adlai Nortye holding rights to AN9025 outside mainland China, Hong Kong and Macao. AN9025 is part of the company’s broader oncology pipeline, which also includes next-generation cancer immunotherapies and additional RAS-targeting candidates.
Venrock-affiliated investment funds and two principals report a passive 6.1% ownership stake in Adlai Nortye Ltd. They beneficially own 9,638,193 ordinary shares, held through American Depositary Shares, each representing three ordinary shares.
The stake is spread across three Venrock Healthcare Capital vehicles, with governance handled by Delaware management entities linked to Nimish Shah and Bong Y. Koh. The ownership percentage is calculated against 93,710,803 ordinary shares outstanding as of June 30, 2025, plus 64,615,386 ordinary shares issued in a February 4, 2026 private placement. The group certifies the shares are not held to change or influence control of Adlai Nortye.
Adlai Nortye Ltd. saw a major institutional holder file an amended ownership report showing it no longer owns any of the company’s American Depositary Shares. Unique Mark Ventures Limited and its parent Fine Process Limited each report beneficial ownership of 0.00 shares, or 0.00% of the class.
The filing explains that Unique Mark Ventures, wholly owned by Fine Process and ultimately linked to ICBC group entities, has disposed of all its shares and ceased to be a shareholder as of this amendment. All voting and dispositive power figures in the report are listed as zero.
Adlai Nortye Ltd. entered into securities purchase agreements for a private placement equity financing expected to raise approximately $140.0 million in gross proceeds, before fees and expenses. The company is selling 64,615,386 Class A ordinary shares, equivalent to 21,538,462 ADSs, at $2.1667 per ordinary share (or $6.50 per ADS).
The private placement, co-led by Cormorant Asset Management and Columbia Threadneedle Investments with several other institutional investors, is expected to close on February 4, 2026, subject to customary conditions. Around $55 million of shares will be purchased by entities controlled by Chairman and CEO Yang Lu. Adlai Nortye agreed to file a registration statement covering resale of the ADSs issued in the financing.
Adlai Nortye Ltd. received a Schedule 13G reporting that Unique Mark Ventures Limited and its parent Fine Process Limited beneficially own 5,750,790 Class A ordinary shares, equal to 6.14% of this class. The position relates to American Depositary Shares, each representing three Class A ordinary shares.
The shares are registered in the name of Unique Mark Ventures Limited, which is wholly owned by Fine Process Limited and, through intermediate entities, ultimately controlled by Industrial and Commercial Bank of China Limited, a PRC state-owned bank and public company. Voting and dispositive power over these shares is exercised on a shared basis, with no sole voting or dispositive power reported.
The 6.14% figure is calculated using 93,710,803 Class A ordinary shares issued and outstanding as of the company’s 2024 annual report, providing investors with an updated view of this institutional holder’s stake.
ANL Talent Limited reported beneficial ownership of 9,300,000 ordinary shares of Adlai Nortye Ltd., representing 7.75% of the company’s ordinary shares outstanding as of December 31, 2025. These shares have sole voting and dispositive power attributed to ANL Talent.
The shares are held through a trust structure for the benefit of certain Adlai Nortye employees under the company’s share incentive plan. ANL Talent is ultimately owned by Trident Trust Company (HK) Limited, which acts as trustee and must follow directions or prior written consent from an advisory committee currently comprising an authorized representative of the issuer, namely Xiao Zhang.
Adlai Nortye reported unaudited first half 2025 results showing a smaller loss and lower cash burn while advancing its oncology pipeline. Net loss for the six months ended June 30, 2025 narrowed to
Cash and cash equivalents were
Adlai Nortye Ltd. submitted a Form 6-K as a foreign private issuer for October 2025. The filing primarily provides materials for an upcoming extraordinary general meeting of shareholders, including a formal notice of the meeting and a proxy card for shareholders to use when voting.
Adlai Nortye Ltd. filed an S-8 registration to register securities for an employee benefit plan. The filing contains the registrant's standard undertakings to file post-effective amendments to include required prospectuses, reflect material changes after effectiveness, and remove unsold securities at the end of the offering. The exhibit list shows a legal opinion on validity of the securities from Maples and Calder (Hong Kong) LLP, auditor consents from BDO China Shu Lun Pan and Mazars USA, a powers of attorney, and a calculation of the filing fee. The form is signed by Yang Lu as Chief Executive Officer and Chairman of the Board and as Director of Adlai Nortye USA Inc.